AIM
SYRS

ARK Investment Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

ARK Investment Management’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-771,172
Closed -$57.7M – 302
2021
Q1 		$57.7M Sell
771,172
-132,960
-15% -$13.8M 0.11% 123
2020
Q4 		$98.1M Sell
904,132
-217,119
-19% -$19.8M 0.26% 72
2020
Q3 		$99.1M Buy
1,121,251
+269,938
+32% +$30.7M 0.59% 44
2020
Q2 		$90.8M Buy
851,313
+261,373
+44% +$23.5M 0.98% 28
2020
Q1 		$35M Buy
589,940
+82,159
+16% +$5.57M 0.87% 29
2019
Q4 		$35.1M Buy
507,781
+124,308
+32% +$7.54M 0.89% 33
2019
Q3 		$39.8M Buy
383,473
+4,297
+1% +$406K 0.87% 33
2019
Q2 		$35.1M Buy
379,176
+79,906
+27% +$5.56M 0.88% 30
2019
Q1 		$27.4M Buy
299,270
+53,208
+22% +$3.71M 0.78% 32
2018
Q4 		$13.7M Buy
246,062
+23,875
+11% +$1.81M 0.56% 35
2018
Q3 		$26.5M Buy
222,187
+42,232
+23% +$4.9M 0.8% 38
2018
Q2 		$18.4M Buy
179,955
+29,466
+20% +$3.65M 0.67% 41
2018
Q1 		$19.5M Buy
150,489
+67,013
+80% +$7.33M 0.97% 34
2017
Q4 		$8.12M Buy
83,476
+70,006
+520% +$9.4M 0.65% 48
2017
Q3 		$1.98M Buy
13,470
+11,699
+661% +$2.2M 0.24% 64
2017
Q2 		$285K Buy
1,771
+946
+115% +$149K 0.06% 93
2017
Q1 		$131K Buy
825
+478
+138% +$58.3K 0.04% 89
2016
Q4 		$42K Buy
+347
New +$48.6K 0.02% 94

Other funds holding SYRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

ARK Investment Management's SYRS Position: Q2 2021 in Review

ARK Investment Management sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2021, closing a stake of 771,172 shares — an estimated $57.7M sold.

ARK Investment Management first reported a position in SYRS in Q4 2016 and held it in 18 quarters. The position peaked at $99.1M in Q3 2020. 100 funds tracked by Wall St. Rank hold SYRS as of Q2 2021.

  • ARK Investment Management reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • ARK Investment Management sold 771,172 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2021, an estimated $57.7M.
  • ARK Investment Management first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 18 quarters.
  • ARK Investment Management's Syros Pharmaceuticals, Inc. Common Stock position peaked at $99.1M in Q3 2020.
  • 100 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2021.

Based on ARK Investment Management's 13F filing for Q2 2021, filed 5 Aug 2021.